SequelSEC

Zivo Bioscience, Inc. ZIVO

Biological Products, (No Diagnostic Substances) · CIK 0001101026 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$209.02K
Fiscal year ended 2025-09-30
Operating income
-$8.46M
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

Valuation, from the filing

Public float$15.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-06-28
Float per share$4.15Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue99.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-28, not today, and each multiple below it uses the figures for the fiscal year ending 2024-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth468.6%92th
SBC / revenue961.1%89th
Current ratio0.80x15th
Net margin-8513.4%16th
Operating margin-8498.9%17th
Gross margin31.1%20th
R&D / revenue1994.0%73th

Zivo Bioscience, Inc. (ZIVO) reported revenue of $209.02K and net income of -$8.49M for the fiscal year ended 2025-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Zivo Bioscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Zivo Bioscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Revenue$209.02K
Cost of revenue$142.82K
Gross profit$66.21K
Operating income-$8.46M
Net income-$8.49M
Research & development$3.70M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.83M
Selling & marketingUnavailable

Balance

Zivo Bioscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Cash & equivalentsUnavailable
Total assets$559.45K
Current assets$281.40K
Total liabilities$3.85M
Current liabilities$3.61M
Total equity incl. NCI-$3.29M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$0
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$992.99K

Cash flow

Zivo Bioscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Operating cash flow-$3.08M
Capital expendituresUnavailable
Investing cash flow$0
Financing cash flow$2.98M
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Zivo Bioscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Free cash flowUnavailable
Gross margin31.7%
Operating margin-4045.7%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.08x
Revenue YoY growth164.5%
Net margin-4059.7%
R&D / revenue1768.1%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZIVO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-03-18View SEC filing
10-Q · Filed 2024-11-14View SEC filing
10-Q · Filed 2024-08-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.